Literature DB >> 11035916

Damage-resistant DNA synthesis in Fanconi anemia cells treated with a DNA cross-linking agent.

S A Centurion1, H R Kuo, W C Lambert.   

Abstract

Fanconi anemia (FA) is a recessive disorder associated with diverse congenital anomalies, progressive bone marrow failure, and a marked predisposition to develop cancer. At the cellular level, FA is characterized by a prolonged G(2) phase in proliferating cells and a marked hypersensitivity to both the cytotoxic and the clastogenic effects of agents which produce DNA interstrand cross-links. Treatment with these agents leads to even further prolongation of the G(2) phase in FA cells. We now show that FA cells, from four different complementation groups, fail to decrease their rates of replicative DNA synthesis, as do normal cells, following treatment with a DNA cross-linking agent. This may be responsible for the prolongation of the G2 phase seen in these cells, and suggests that the fundamental defect in response of FA cells to DNA cross-linking agents may be in the S phase, rather than the G(2) phase, of the cell cycle. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11035916     DOI: 10.1006/excr.2000.4995

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  14 in total

Review 1.  Fanconi anaemia.

Authors:  M D Tischkowitz; S V Hodgson
Journal:  J Med Genet       Date:  2003-01       Impact factor: 6.318

2.  The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response.

Authors:  Min Huang; Jung Min Kim; Bunsyo Shiotani; Kailin Yang; Lee Zou; Alan D D'Andrea
Journal:  Mol Cell       Date:  2010-07-30       Impact factor: 17.970

3.  Cho Endonuclease Functions during DNA Interstrand Cross-Link Repair in Escherichia coli.

Authors:  Anthonige Vidya Perera; James Brian Mendenhall; Charmain Tan Courcelle; Justin Courcelle
Journal:  J Bacteriol       Date:  2016-10-21       Impact factor: 3.490

4.  BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.

Authors:  Céline J Rocca; Daniele G Soares; Hana Bouzid; João A P Henriques; Annette K Larsen; Alexandre E Escargueil
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer.

Authors:  Jung Wook Park; Henry C Pitot; Katerina Strati; Nicole Spardy; Stefan Duensing; Markus Grompe; Paul F Lambert
Journal:  Cancer Res       Date:  2010-10-08       Impact factor: 12.701

6.  Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination.

Authors:  Kazuhiko Yamamoto; Seiki Hirano; Masamichi Ishiai; Kenichi Morishima; Hiroyuki Kitao; Keiko Namikoshi; Masayo Kimura; Nobuko Matsushita; Hiroshi Arakawa; Jean-Marie Buerstedde; Kenshi Komatsu; Larry H Thompson; Minoru Takata
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

Review 7.  Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

Authors:  Larry H Thompson; John M Hinz
Journal:  Mutat Res       Date:  2009-02-21       Impact factor: 2.433

8.  Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice.

Authors:  Scott Houghtaling; Cynthia Timmers; Meenakshi Noll; Milton J Finegold; Stephen N Jones; M Stephen Meyn; Markus Grompe
Journal:  Genes Dev       Date:  2003-07-31       Impact factor: 11.361

9.  The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways.

Authors:  Alexandra Sobeck; Stacie Stone; Igor Landais; Bendert de Graaf; Maureen E Hoatlin
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

10.  Checkpoint signaling from a single DNA interstrand crosslink.

Authors:  Merav Ben-Yehoyada; Lily C Wang; Ivan D Kozekov; Carmelo J Rizzo; Max E Gottesman; Jean Gautier
Journal:  Mol Cell       Date:  2009-09-11       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.